Filing Details
- Accession Number:
- 0001209191-11-055813
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2011-11-14 17:11:01
- Reporting Period:
- 2011-11-11
- Filing Date:
- 2011-11-14
- Accepted Time:
- 2011-11-14 17:11:01
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
858803 | Avanir Pharmaceuticals Inc. | AVNR | Pharmaceutical Preparations (2834) | 330314804 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1280154 | Christine Ocampo | 20 Enterprise, Suite 200 Aliso Viejo CA 92656 | Vice President, Finance | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2011-11-11 | 3,750 | $1.20 | 44,672 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2011-11-11 | 12,000 | $0.88 | 56,672 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2011-11-11 | 12,000 | $0.88 | 68,672 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2011-11-11 | 64,500 | $0.88 | 133,172 | No | 4 | M | Direct | |
Common Stock | Disposition | 2011-11-11 | 92,250 | $2.62 | 40,922 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock option (right to buy) | Disposition | 2011-11-11 | 3,750 | $0.00 | 3,750 | $1.20 |
Common Stock | Stock option (right to buy) | Disposition | 2011-11-11 | 12,000 | $0.00 | 12,000 | $0.88 |
Common Stock | Stock option (right to buy) | Disposition | 2011-11-11 | 12,000 | $0.00 | 12,000 | $0.88 |
Common Stock | Stock option (right to buy) | Disposition | 2011-11-11 | 64,500 | $0.00 | 64,500 | $0.88 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2017-03-29 | No | 4 | M | Direct | |
4,000 | 2018-07-25 | No | 4 | M | Direct | |
15,000 | 2018-07-25 | No | 4 | M | Direct | |
38,700 | 2018-07-25 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 11,900 | Indirect | By spouse |
Footnotes
- Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting Person, which are subject to certain vesting conditions.
- The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Following the sales reported on this Form 4, the Reporting Person has a total of 118,138 options to purchase shares of common stock that are vested and immediately exercisable and 257,112 options to purchase shares of common stock that have not yet vested. Following the sales reported on this Form 4, the Reporting Person also has 11,250 unvested Restricted Stock Units.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.62 to $2.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The Reporting Person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
- The option vested with respect to 6.25% of the underlying shares upon the achievement of certain performance goals and continues to vest on a quarterly basis over 15 quarters from the initial vesting of the 6.25% upon the achievement of the performance goals.